Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advantage of switching from preserved to preservative-free treatments for glaucoma
2011-004617-16Phase 4Completed
- Sponsor
- ASST Santi Paolo e Carlo
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tafluprost in Glaucoma (2 arms), sponsored by ASST Santi Paolo e Carlo. Primary endpoint: Corneal sub-basal nerve fiber layer density in four limbal regions. Started Jan 2012; status: completed.
02
Drugs
tafluprost
03
Conditions
Glaucoma
Beyond the preview
Go deeper on 2011-004617-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004617-16.